Research & Development

Survey: Half of women don't focus on their own health

Survey: Half of women don't focus on their own health

By

GCI Health, HealthyWomen, and Redbook magazine are using survey insights to inform the HealthiHer movement.

ePharma: Boehringer Ingelheim and Aptus Health partner for asthma brand awareness

ePharma: Boehringer Ingelheim and Aptus Health partner for asthma brand awareness

Jim Boushie, director of respiratory marketing at Boehringer Ingelheim (BI) and David Laros, VP of analytics and commercial effectiveness at Aptus Health, came together to lead a joint ePharma session in March titled "Synchronized HCP and consumer campaigns: At the point of care and beyond."

Marketers discuss catalysts for use of behavioral science techniques

Marketers discuss catalysts for use of behavioral science techniques

By

Marketers discuss the biggest catalysts for use of behavioral science techniques in marketing.

Machine Learning Can Decipher Data

Machine Learning Can Decipher Data

As researchers and analysts, we interact with a wide array of market research pros in the health and wellness space.

Five things for pharma marketers to know: Thursday, January 11, 2018

Five things for pharma marketers to know: Thursday, January 11, 2018

By

Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations

Cancer Research UK 'Right Now' campaign returns to highlight research impact

Cancer Research UK 'Right Now' campaign returns to highlight research impact

By

Cancer Research UK's 'Right Now' brand campaign will return in 2018 with a new focus highlighting the impact that research has on people suffering with cancer.

Five things for pharma marketers to know: Thursday, December 14, 2017

Five things for pharma marketers to know: Thursday, December 14, 2017

By

Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business

Gottlieb Eyes Prices, Not Lives

Gottlieb Eyes Prices, Not Lives

It turns out the real goal is going after Washington's favorite whipping boy — high drug prices.

Five things for pharma marketers to know: Wednesday, December 6, 2017

Five things for pharma marketers to know: Wednesday, December 6, 2017

By

FDA approves Novo's diabetes drug; Walgreens undergoes rebranding in the wake of CVS-Aetna merger; pharma increasingly transparent about clinical trial data

Looking Beyond Overall Survival

Looking Beyond Overall Survival

Our understanding of how cancer develops and thrives has grown.

Five things for pharma marketers to know: Thursday, November 2, 2017

Five things for pharma marketers to know: Thursday, November 2, 2017

By

Teva reports lower-than-expected Q3 earnings; BI and Dicerna partner in NASH drug development; AstraZeneca's experimental asthma drug fails in Phase-III

Who's Getting Rich in Healthcare?

Who's Getting Rich in Healthcare?

Do you recall what President Trump tweeted right after Merck's Kenneth Frazier resigned from his American Manufacturing Council?

Five things for pharma marketers to know: Thursday, October 26, 2017

Five things for pharma marketers to know: Thursday, October 26, 2017

By

Non-profit challenges Gilead's Sovaldi patent; The Medicines Company to cut hundreds of jobs; Amgen ends R&D for experimental CETP drug

Nonprofits focus attention on metastatic breast cancer this October

Nonprofits focus attention on metastatic breast cancer this October

By

Susan G. Komen and the Breast Cancer Research Foundation are focusing on raising awareness and research money for the deadliest forms of the disease.

AI Drug Design Could Save Lives

AI Drug Design Could Save Lives

AI complements what we in pharma have always done best — respond to medical needs quickly and find solutions.

Five things for pharma marketers to know: Tuesday, May 16, 2017

Five things for pharma marketers to know: Tuesday, May 16, 2017

By

A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms

Five things for pharma marketers to know: Tuesday, May 9, 2017

Five things for pharma marketers to know: Tuesday, May 9, 2017

By

Sanofi ties price increases to growth rate; Regeneron to target 7,000 docs on new eczema drug Dupixent; NIH and biotech execs meet White House officials

Pharma R&D partnerships are on the rise: report

Pharma R&D partnerships are on the rise: report

By

This is likely due, in part, to the increasingly complex nature of new specialty drugs.

In Merck video, woman says a cure is the greatest invention

In Merck video, woman says a cure is the greatest invention

By

The drugmaker's video asks people in New York and San Francisco about their ideas for great inventions.

Large teaching hospitals more prone to breaches

Large teaching hospitals more prone to breaches

By

These facilities may be more prone to attack because there are more people at them with access to private patient data, whether to conduct medical research or educate new healthcare professionals.

Five things for pharma marketers to know: Friday, March 24, 2017

Five things for pharma marketers to know: Friday, March 24, 2017

By

Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

By

Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices

Five things for pharma marketers to know: Wednesday, March 8, 2017

Five things for pharma marketers to know: Wednesday, March 8, 2017

By

Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs

When It Comes to the FDA, Does It All Come Down to Money?

When It Comes to the FDA, Does It All Come Down to Money?

In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?

Is the Trump Administration the Cure the FDA Needs?

Is the Trump Administration the Cure the FDA Needs?

Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.

Five things for pharma marketers to know: Tuesday, February 21, 2017

Five things for pharma marketers to know: Tuesday, February 21, 2017

By By

Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena

Five things for pharma marketers to know: Monday, February 6, 2017

Five things for pharma marketers to know: Monday, February 6, 2017

By

Novo Nordisk CEO describes 'volatile' pricing environment; Lilly to cut 200 research and development jobs; pharma opts out of Super Bowl this year

Five things for pharma marketers to know: Monday, January 9, 2017

Five things for pharma marketers to know: Monday, January 9, 2017

By

Takeda to acquire Ariad for $4.6 billion, Merck pairs with Incyte for Keytruda combo drug collaboration; Sanofi announces autoimmune research deal

QuintilesIMS taps Staub as head of R&D solutions

QuintilesIMS taps Staub as head of R&D solutions

By

The merger of Quintiles and IMS Health closed in October.

Sermo and Everyday Health partner in advertising-research deal

Sermo and Everyday Health partner in advertising-research deal

By

The partnership allows Sermo to expand the reach of its research initiatives and Everyday Health to scale its targeted advertising on the social platform.